US Patent 6,743,441: Oxybutynin Transdermal Patent Scope, Expiration, and Competitive Landscape

US Patent 6,743,441 protects a pharmacokinetic profile for transdermal oxybutynin therapy rather than a patch architecture alone. The core invention links transdermal delivery to reduced exposure to N-desethyloxybutynin, the metabolite associated with anticholinergic adverse effects, particularly dry mouth. The patent covers both treatment methods and an article of manufacture, with dependent claims directed to stereochemistry, metabolite concentration, AUC relationships, permeation enhancers, and patch duration.

The patent’s practical commercial value was tied to Oxytrol, a transdermal oxybutynin system developed and commercialized by Watson Pharmaceuticals, now part of AbbVie through the Actavis and Allergan transactions. The patent’s ordinary 20-year term has expired, removing it as a current US blocking right, although its claims remain relevant to historical Orange Book analysis, infringement disputes, and freedom-to-operate reviews.

What does US Patent 6,743,441 protect?

US 6,743,441 protects transdermal administration of oxybutynin that produces specified plasma exposure relationships between oxybutynin and its metabolite. The patent does not require one particular patch construction, reservoir, adhesive, backing layer, or membrane.

Its principal limitations are:

Limitation	Claim requirement
Therapeutic indication	Overactive bladder
Active ingredient	Oxybutynin
Delivery route	Transdermal patch
Pharmacokinetic result	Oxybutynin-to-metabolite AUC ratio of about 0.5:1 to about 5:1
Clinical objective	Minimization of an anticholinergic or antimuscarinic adverse drug experience
Optional excipient	Permeation enhancer
Named metabolite	N-desethyloxybutynin
Covered dosage forms	Transdermal patch and article of manufacture
Duration limitations	Generally 24 to 96 hours in dependent claims

The patent’s central theory is that transdermal delivery avoids or reduces first-pass metabolism of oxybutynin. Oral oxybutynin produces higher exposure to N-desethyloxybutynin, while transdermal administration produces a higher parent-drug-to-metabolite relationship and fewer anticholinergic adverse effects. The specification and claims use pharmacokinetic results as the main boundary of protection. (U.S. Patent No. 6,743,441, 2004)

What are the independent claims in US 6,743,441?

Claim 1: transdermal treatment method

Claim 1 requires all of the following:

A subject having overactive bladder.
Treatment with oxybutynin.
Administration through a transdermal patch.
A composition that produces an oxybutynin-to-oxybutynin-metabolite plasma AUC ratio of about 0.5:1 to about 5:1.
Minimization of an anticholinergic or antimuscarinic adverse drug experience.

The claim is therefore a method-of-treatment claim with a pharmacokinetic limitation. A patch containing oxybutynin would not necessarily infringe merely because it uses the same active ingredient or treats overactive bladder. The accused product would need to produce the claimed exposure profile, and the treatment would need to satisfy the adverse-experience limitation.

The claim covers racemic oxybutynin, R-oxybutynin, S-oxybutynin, and combinations, based on dependent claims 4 and 31-33. It also covers patches with or without a permeation enhancer.

Claim 15: article of manufacture

Claim 15 covers an article of manufacture comprising:

A transdermal patch;
A composition containing oxybutynin;
An optional permeation enhancer;
A composition that produces the specified AUC ratio; and
A patch that minimizes an anticholinergic or antimuscarinic adverse drug experience.

Claim 15 is broader in product form than a claim limited to a named commercial patch design, but it remains constrained by the pharmacokinetic and functional language. The product claim is not limited to a particular adhesive, membrane, backing, patch area, oxybutynin loading, or delivery rate.

How do the dependent claims expand patent coverage?

The dependent claims divide into five principal technical groups.

AUC ratio claims

Claims 2, 3, 16, 17, 44-47 and related claims narrow the parent-drug-to-metabolite AUC relationship.

The key ranges are:

Claims	AUC limitation
1, 15	Oxybutynin/metabolite about 0.5:1 to about 5:1
2, 16	About 1:1 to about 5:1
3, 17	About 0.8:1 to about 1.5:1
44	Oxybutynin/N-desethyloxybutynin about 0.5:1 to about 4:1
45	About 1:1 to about 5:1
46	About 0.8:1 to about 2.5:1

Claims 3 and 17 are commercially important because they define a narrower range around approximately equal exposure to oxybutynin and its metabolite. Claims 44-46 expressly identify N-desethyloxybutynin and may have been more relevant to product-specific infringement analysis than the broader claims.

Peak plasma concentration claims

Claims 12, 13, 26, 27 and 39-43 define peak metabolite concentrations:

Less than about 8 ng/mL;
Less than about 5 ng/mL;
About 0.5 to about 8 ng/mL;
About 1.0 to about 3 ng/mL; and
About 3 ng/mL.

These limitations create a second infringement pathway. A product could fall within the claimed AUC range but outside the claimed peak concentration range, or vice versa.

Stereochemical claims

Claims 4, 6-11, 18, 20-25, 31-33 and 36-38 address the enantiomers of oxybutynin and N-desethyloxybutynin.

Important stereochemical limitations include:

Claim	Stereochemical relationship
7, 21	R-oxybutynin/S-oxybutynin AUC ratio about 0.7:1
8, 22	R-N-desethyloxybutynin/R-oxybutynin AUC ratio about 0.4:1 to about 1.6:1
9, 23	Same ratio about 1:1
10, 24	R-N-desethyloxybutynin/S-N-desethyloxybutynin about 0.5:1 to about 1.3:1
11, 25	Same ratio about 0.9:1
54	R-metabolite peak concentration and AUC no greater than S-metabolite
55	R-oxybutynin exposure approximately equal to R-metabolite exposure

The claims cover racemic products and single-enantiomer products. The inclusion of R-oxybutynin and S-oxybutynin increases formal claim breadth, but those claims remain dependent on transdermal delivery and the specified pharmacokinetic outcomes.

Concentration-at-timepoint claims

Claims 48-53 and 56-62 define concentration thresholds at six hours, 24 hours, and steady state. Examples include:

Oxybutynin below about 2.0 ng/mL at six hours;
N-desethyloxybutynin below about 2.0 ng/mL at six hours;
Both compounds below about 8 ng/mL at 24 hours;
Both compounds below about 8 ng/mL during steady state;
R-N-desethyloxybutynin below about 1 ng/mL at six hours;
R-N-desethyloxybutynin below about 2 ng/mL at 24 hours;
R-N-desethyloxybutynin peak concentration between about 0.25 and 4 ng/mL;
R-N-desethyloxybutynin AUC of about 30 to 170 ng·hr/mL.

These claims are useful in product testing because they identify measurable pharmacokinetic characteristics. They also create potential validity and enablement issues if the claimed ranges depend materially on study population, analytical method, patch wear time, sampling schedule, dose, or steady-state conditions.

Permeation-enhancer claims

Claims 29, 30, 34 and 35 cover patches using specified permeation enhancers, including:

Fatty acids;
Fatty acid esters;
Fatty alcohols;
Fatty acid esters of lactic or glycolic acid;
Glycerol monoesters, diesters and triesters;
Triacetin;
Short-chain alcohols; and
Mixtures.

Triacetin is expressly claimed in claims 30 and 35. These claims are narrower than the independent claims because they require the additional excipient limitation.

What formulations are protected by US 6,743,441?

The patent protects transdermal compositions containing oxybutynin that generate the claimed plasma profile. It does not require a specific commercial formulation.

The claims potentially reach:

Matrix patches;
Reservoir patches;
Adhesive drug-in-matrix systems;
Patches containing racemic oxybutynin;
Patches containing R-oxybutynin;
Patches containing S-oxybutynin;
Patches using triacetin; and
Patches using other listed permeation enhancers.

The claims do not, on their face, require a particular oxybutynin dose, patch size, adhesive chemistry, backing material, release membrane, or nominal wear interval. Claims 52 and 53 narrow the duration to approximately 24 to 96 hours, but the independent claims do not impose that limitation.

From an infringement perspective, formulation similarity is less important than the resulting pharmacokinetic profile. A technically different patch could fall within the claims if it produces the claimed AUC and concentration relationships.

When did US Patent 6,743,441 lose exclusivity?

US Patent 6,743,441 issued on June 1, 2004. Its statutory term was generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment and any applicable patent-term extension. Public patent records identify the patent as an oxybutynin transdermal patent associated with Watson Pharmaceuticals. (U.S. Patent and Trademark Office, n.d.)

The patent’s ordinary term expired around 2020 or 2021, depending on the effective filing date and any patent-term adjustment. It is therefore an expired US patent and is not a current enforceable barrier to a new generic transdermal oxybutynin product.

Event	Date or period
Patent issued	June 1, 2004
Statutory term	Approximately 20 years from effective nonprovisional filing
Expected expiration	Approximately 2020-2021
Current status	Expired by ordinary term
Current blocking value	None as an enforceable US patent right

Patent expiration does not invalidate the historical significance of the claims. It can still affect prior-art analysis, prosecution history, historical Paragraph IV strategy, and interpretation of older settlement agreements.

What is the Orange Book status of oxybutynin transdermal products?

Oxytrol was approved by the FDA as a prescription transdermal oxybutynin product and later approved for nonprescription use. The product contains oxybutynin and is indicated for overactive bladder symptoms, including urge urinary incontinence, urgency, and frequency. The FDA approved the nonprescription version for women aged 18 years and older. (U.S. Food and Drug Administration, 2013)

The Orange Book historically listed patents associated with the Oxytrol NDA, including US 6,743,441. Because the patent has expired, it no longer supports a current period of Orange Book patent exclusivity. Orange Book listing also does not mean that every generic transdermal system would necessarily infringe every claim. The claims require specific pharmacokinetic and clinical characteristics.

The regulatory position differs from the patent position:

Issue	Status
Active ingredient	Oxybutynin
Drug class	Antimuscarinic
Original product	Oxytrol transdermal system
FDA pathway	NDA approval; later OTC switch
Patent 6,743,441	Expired
Biosimilar pathway	Not applicable
Generic pathway	ANDA or other applicable small-molecule pathway
Current patent barrier	No enforceable barrier from 6,743,441

Which companies challenged or competed with Oxytrol?

The competitive field included oral oxybutynin, alternative transdermal products, topical oxybutynin gel, and other overactive bladder therapies.

Product	Active ingredient	Delivery	Competitive relevance
Oxytrol	Oxybutynin	Transdermal patch	Direct product associated with the patent
Ditropan and generics	Oxybutynin	Immediate-release oral	Lower-cost oral competition
Ditropan XL and generics	Oxybutynin	Extended-release oral	Competes on dosing convenience
Gelnique	Oxybutynin	Topical gel	Alternative nonoral delivery
Toviaz	Fesoterodine	Oral	Competing antimuscarinic
Enablex	Darifenacin	Oral	Competing antimuscarinic
Vesicare	Solifenacin	Oral	Competing antimuscarinic
Myrbetriq	Mirabegron	Oral beta-3 agonist	Non-anticholinergic competitor

The principal technical differentiator for Oxytrol was reduced metabolite exposure relative to oral oxybutynin. A generic transdermal product would need to match FDA requirements for quality, delivery performance, adhesion, safety, and efficacy. Patent 6,743,441 is no longer the principal obstacle, but formulation development and regulatory equivalence remain relevant barriers.

What Paragraph IV and litigation risks affected US 6,743,441?

A Paragraph IV certification would have been relevant during the patent’s enforceable term if an ANDA applicant asserted that the patent was invalid, unenforceable, or not infringed. The claim set created several potential design-around and litigation issues:

Whether an ANDA product produces the claimed oxybutynin-to-metabolite AUC ratio.
Whether the product minimizes an anticholinergic adverse experience.
Whether “about” provides a sufficiently definite boundary.
Whether the claims are enabled across the full AUC and concentration ranges.
Whether a product-specific pharmacokinetic study can establish or defeat infringement.
Whether the article-of-manufacture claims are improperly functional or indefinite.
Whether the claims improperly recite a result without sufficient structural limitations.

No current litigation risk remains from this patent because an expired patent cannot support a new US infringement action based on post-expiration conduct. Historical litigation or settlement agreements, if any, would have to be evaluated against the patent’s expiration date and the specific ANDA filing timeline.

How strong was the patent estate for transdermal oxybutynin?

Strengths

The patent had several commercial strengths during its term:

It covered the core transdermal treatment concept.
It used pharmacokinetic outcomes closely associated with the clinical rationale for the product.
It covered both treatment methods and an article of manufacture.
It included racemic and single-enantiomer oxybutynin.
It included metabolite AUC, peak concentration, timepoint concentration, and steady-state limitations.
It did not depend on one narrow patch construction.
It expressly included permeation enhancers, including triacetin.

Weaknesses

The claim structure also created vulnerabilities:

The independent claims require proof of a pharmacokinetic result.
AUC ratios can vary with dose, sampling interval, assay method, patient population, metabolism, patch wear, and study design.
“About” ranges may create uncertainty at the boundaries.
“Minimizing” an adverse drug experience is functional and potentially difficult to measure.
The claims refer to “an oxybutynin metabolite” before narrowing to N-desethyloxybutynin.
Some dependent claims contain drafting irregularities, including the phrase “where the permeation enhancer” and claim 29’s dependence on method claim 1.
A competitor could potentially design around the claimed profile by changing delivery rate, dose, stereoisomer composition, or metabolite exposure.

The estate was strongest against products that reproduced the Oxytrol-type pharmacokinetic profile. It was weaker against products using a materially different delivery profile or a different therapeutic formulation that did not meet the claimed ranges.

What generic launch scenarios existed after patent expiry?

After expiration, three launch scenarios became available.

Direct transdermal generic

A sponsor could develop a transdermal oxybutynin system and seek FDA approval through an applicable abbreviated or hybrid pathway. The principal work would involve demonstrating drug release, adhesion, delivery consistency, safety, and therapeutic equivalence.

Reformulated patch

A sponsor could use a different adhesive, matrix, patch size, loading, or permeation enhancer. Because 6,743,441 is expired, the design would not need to avoid its claims for current US launch purposes, but a sponsor would still need to review any later patents covering the specific formulation or device.

Alternative oxybutynin delivery

A sponsor could pursue topical gel, oral extended release, or another dosage form. Such products would not ordinarily implicate the transdermal-patch limitations of claims 1 and 15.

The commercial opportunity depends on whether the prescription and OTC markets are served by the same product, whether the FDA requires a new drug application rather than an ANDA, and whether later formulation or device patents remain active.

How does US 6,743,441 compare with competing oxybutynin IP?

Feature	US 6,743,441	Conventional oral oxybutynin patents	Topical gel patents
Primary protection	PK profile and clinical effect	Release profile, dosage form, or method	Gel composition and skin delivery
Delivery route	Transdermal patch	Oral	Topical gel
Key metabolite	N-desethyloxybutynin	Often not central	May be relevant but not necessarily limiting
Claim type	Method and article of manufacture	Product, formulation, method	Composition, method, delivery
Stereochemistry	Expressly covered	Depends on patent	Depends on patent
Status of 6,743,441	Expired	Patent-specific	Patent-specific
Biosimilar relevance	None	None	None

Key Takeaways

US 6,743,441 is centered on transdermal oxybutynin that produces a specified oxybutynin-to-N-desethyloxybutynin exposure profile.
Claims 1 and 15 are the principal independent claims.
The patent covers treatment methods and patches, not a single patch design.
Dependent claims address AUC ratios, peak concentrations, steady-state concentrations, stereoisomers, triacetin, and 24-to-96-hour administration.
“Minimizing” anticholinergic adverse experiences and the pharmacokinetic limitations are central claim-construction and infringement issues.
The patent’s ordinary term expired around 2020-2021.
It is no longer an enforceable US barrier to generic transdermal oxybutynin entry.
Oxybutynin is a small molecule, so biosimilar analysis does not apply.
Current generic risk turns more on FDA approval requirements, commercial demand, and later formulation or device patents than on US 6,743,441.
The patent was strongest against products reproducing the Oxytrol-type parent-drug and metabolite profile.

FAQs

Does US Patent 6,743,441 cover all oxybutynin patches?

No. It covers patches that satisfy the claimed pharmacokinetic and clinical limitations. A patch containing oxybutynin is not automatically within the claims.

Does the patent cover oral oxybutynin?

No. The independent claims require administration through a transdermal patch.

Is N-desethyloxybutynin the key metabolite in the patent?

Yes. Claims 5, 19, 39-62 and related claims expressly identify N-desethyloxybutynin and define its AUC and plasma concentration characteristics.

Could a single-enantiomer oxybutynin patch fall within the patent?

Yes. Claims 4, 18, 31-33 and 36-38 expressly cover R-oxybutynin, S-oxybutynin, and mixtures, subject to the parent claims’ transdermal and pharmacokinetic limitations.

Does patent expiration eliminate FDA requirements for a generic patch?

No. Expiration removes the patent barrier but does not eliminate FDA requirements for approval, product quality, adhesion, drug release, safety, efficacy, and therapeutic equivalence.

References

U.S. Patent No. 6,743,441. (2004). Methods and compositions for transdermal delivery of oxybutynin. U.S. Patent and Trademark Office.
U.S. Food and Drug Administration. (2013). FDA approves first over-the-counter treatment for overactive bladder. https://www.fda.gov/
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension information. https://www.uspto.gov/learning-and-resources/fees-and-payment/patent-term-adjustment---

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	488233	⤷ Start Trial
Australia	2001253782	⤷ Start Trial
Australia	2003287377	⤷ Start Trial
Australia	2003294239	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,743,441

Summary for Patent: 6,743,441